The “external fixators” (FixEx) used to date have already provided the outstanding service of stabilizing bone fractures in case of serious injuries, open bone fractures and severe joint fractures for decades.With all “external fixator” systems, four to six bone pins are screwed through the skin and into the bone. A fixation device (the actual “external fixator”) is then attached to these bone pins externally. Very often so-called “trauma fixators” are then removed after a few days or weeks once the patient’s overall condition has stabilized. The bone fracture is then definitively stabilized using a plate and screws or intramedullary nails. However, mounting the “external fixator” systems that are currently on the market is enormously time-consuming and error-prone and can only be reliably implemented by experienced orthopedic surgeons.
The technical invention “snake FX” by the Erlangen-based startup nice!innovations GmbH has profoundly revolutionized the “external fixator” and its use in orthopedics and accident surgery. It is a conceptually completely new and an already well-developed product that enables an enormously clever, incomparably fast, incredibly simple method for stabilization of bone fractures by means of an unprecedented “snake principle”. Its “one-step rapid fixation technology” allows “snakeFX” to both fix the external fixator to the bone pins and stabilize the “FixEx” in a single step! Using traditional external fixator systems, both tasks involved time-consuming and error-prone mounting operations. Patents for “snake FX” have already been awarded for Europe, US, Brazil and Japan!
Precisely these unique selling points are leveraged when it comes to distribution: An initial estimate from Switzerland illustrates the high cost-saving potential combined with a dramatic increase in the quality of care for the patient. In Switzerland, one minute in the operating room costs 80 CHF. It takes trained orthopedic and trauma surgeons anywhere from 60 to 120 minutes for mounting and to make fine adjustments. The “snakeFX” aims to reduce this time to about 15 minutes.
nice!innovations GmbH is currently developing the “snakeFX” into an approved product that is ready for series production. A crowd-financing campaign on www.aescuvest.de had collected more than 260,000 euros for this purpose as of February 2016 (in the form of subordinated loans). Following successful prototyping (expected in Q3/2017), snakeFX can obtain CE approval and be prepared for series production (target Q3/2018) within 9 to 12 months. The service provider for carrying out CE certification (Risk Class 1s; assessment by the “Notified Bodies” is available) has already been commissioned; a usability study with trauma surgeons, prototype-testing in a certified testing laboratory and a clinical trial are currently being conceptualized and implemented. An investor or strategic partner is being sought for the subsequent international commercialization of “snakeFX”.
Jörg Trinkwalter is a member of the Executive Board of the cluster management organization Medical Valley Europäische Metropolregion Nürnberg (EMN) e.V., as well as registered manager of the incubator Medical Valley Center in Erlangen/Germany. Medical Valley EMN is considered as one of the most dynamic medical technology regions worldwide and was awarded national cluster of excellence by the German Ministry of Education and Research in 2010. In 2015 Jörg Trinkwalter co-founded the two medical technology startup companies nice!innovations GmbH and TBrace GmbH in the orthopedic area and acts as CEO of these companies. nice!innovations GmbH raised 262.000 € in 2016 via a crowdfinancing campaign on www.aescuvest.de in order to develop the new fixateur externe-concept “snakeFX” market-ready.
Launched in Jan-2016, Paragate Medical is an Israeli innovative startup, aiming to revolutionize the heart failure epidemic management by introducing the first implantable medical device that actively and continuously prevents fluid overload in congestive heart failure patients. The device absorbs systemic extracellular fluid and drains it to the urinary system in a safe and controlled manner.
With its encouraging pre-clinical results and strong IP coverage, the company is currently looking to complete series A to support European based operation towards FIM trials.
Paragate's IPU is a minimally invasive, fully implantable device that continuously and actively drains excess systemic extracellular fluid, maintaining fluid overloaded heart failure patients in normal volumes and reducing the need for repeated hospitalizations for acute treatments.
CEO and Co-founder of Paragate Medical. Over 11 years’ experience in cardiovascular devices field in R&D engineering and management positions, from which 7 with Enopace Biomedical, pioneering the conceptualization and development of intravascular neurostimulation device. Holds B.Sc. in BME from the Technion, resulting in a spinoff startup (Pneumedicare) and an M.Sc. in BME from the Technion-IIT, awarding him with ISHR young investigator award for the research in cardiac resynchronization therapy.
Portabiles HealthCare Technologies GmbH
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Portabiles HealthCare Technologies GmbH has been founded in Nürnberg, Germany, in Dec/2016 by an experienced Management and scientific Team: Ralph Steidl (CEO), Prof. Dr. med. Jochen Klucken (University Hospital Erlangen), Prof. Dr. Björn Eskofier (University Erlangen-Nürnberg). The team works closely together since more than seven years and holds extensive competences in the fields of movement disorders, healthcare platforms, wearable technology, machine learning, data mining, and general management.
gait analysis, wearables, Medical Device, sensors, algorithms, falls prevention,
Year Founded
2016
Financial Summary
We raised in total 645.000 € through shareholder capital, convertible loans, public funding.
For medical device development, approval in Europe and US, and for sales efforts, another 1 M € are required.
Pipeline Product 1: Name/Stage
Mobile GaitLab
Product 1: Description
Worsening of the human gait is an important symptom in many chronic diseases and reason for most of the falls of elderly. An objective analysis of a patient's gait during activities of daily living delivers valuable information about the progress of a disease, the efficacy of a therapy (or a new drug), and the patient’s individual risk of falling. Mobile GaitLab consists of motion sensors integrated into the patient's shoes (prepared orthopedic shoes). They measure the gait dynamics and provide clinical grade gait parameters to the therapist (Medical Device class IIa). Doctors thereby will be able to adjust therapy solely based upon those data. Mobile GaitLab supports clinical trials for proving the efficacy of new drugs, tele-healthcare concepts (e.g. medication adjustment in Parkinson's Disease), and at a later stage prevention of falls.
Ralph Steidl, former Managing Director of Astrum IT (a medium sized SW company) has more than 15 years of experience in Management and Sales in IT and Telecommunication Industries and a high level of expertise in Digital Health and Medical Devises Development. He led many interdisciplinary R&D projects dealing with IT-interconnection in Healthcare and clinical grade wearable technologies.
RetinAI Medical GmbH
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
RetinAI Medical is a Swiss company that supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence (AI). Our vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma.
Our solutions rely on the latest advances in medical image analysis, ophthalmology and machine learning. We have a unique team of scientists working to fully realize the capabilities of AI, and to integrate this technology into the next generation of medical devices.
CEO and Co-Founder of RetinAI and PhD in machine learning and medical imaging in ophthalmology.
RiboStruct
Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
RiboStruct is developing the first generic treatment for genetic diseases.
RiboStruct leverages the long-term work of Marat Yusupov and Gulnara Yusupova on the crystallographic study of the eukaryotic ribosome to develop new drugs, in particular "readthrough compounds" targeting the human ribosome for the treatment of monogenic genetic diseases when they are caused by nonsense mutations (10-15% of cases). Distinctively from gene therapies, where a specific program is needed for each disease, RiboStruct develops a pharmacological "protein repair therapy" approach, with the goal to cure multiple diseases with the same molecule by acting on a common mechanism. More than 7000 genetic diseases have been described so far, affecting altogether 300 million people worlwide.
Aminoglycosides are known to help the ribosome overcome premature stop codons to restore the synthesis of full-length proteins but their high toxicity prevents their use on the long term as needed for the treatment of monogenic diseases caused by nonsense mutations.
RiboStruct is developing non-aminoglycoside readthrough compounds using a fragment- and structure-based drug design approach relying on an exclusive know-how on the crystallographic structure determination of the whole eukaryotic ribosome in complex with ligands and on the strong biophysical capabilities of its strategic partner NovAliX (http://www.novalix-pharma.com/).
Jean-Paul Renaud created RiboStruct as a spinoff company from IGBMC (Illkirch, France) end of 2015.
He was previously cofounder and CSO Science & Technology at NovAliX (2010-2014), creator and President & CEO-CSO at AliX (2002-2008), and CNRS Research Director at IGBMC (2000-2002).
Jean-Paul holds an Engineering Diploma from ENSCP (1982) and a PhD in Organic Chemistry from UPMC (1986).
Awards :
2017 Laureate, 19th French National Innovative Startup Competition (i-LAB 2017) (for RiboStruct) 2006 Laureate, Réseau Entreprendre Alsace (for AliX) 2002 Laureate, 4th French National Innovative Startup Competition (i-LAB 2002) (for AliX) 1986 Eugène Schueller Prize
Scailyte AG
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Scailyte AG is an innovative Swiss-based company developing artificial intelligence (AI) technology for clinical research and diagnostics. We are offering a unique solution for the discovery of novel biomarkers for ultra-sensitive and early diagnosis of complex diseases such as cancer.
TechsoMed is an Israeli based medical device company, developing BioTrace™, a real-time, monitoring and control system for thermal ablation procedures. The technology is applicable to multiple fields such as Oncology (tumor ablation), Cardiac (arrhythmia) and Pain management. Our breakthrough technology (based on two granted patents) is the only one which can give physicians real time monitoring and control for ablation procedures, and it can do all that by interfacing with standard ultrasound devices. The control and security we can give physicians will make our system a must-have for major ablation treatments.
BioTrace™ - Transforming the way Thermal ablations are doneBioTrace – IO World’s first real time monitoring and control system for thermal ablation procedures such as solid tumors.
Interfacing with standard ultrasound devices that can be found in almost every clinic / hospital around the world.
Does not change the way the ablation procedure is done, allowing for fast regulatory approval.
Closed loop treatments with continuous feedback to measure therapy outcomes and to achieve the desired results.
successfully advanced through proof of concept , working prototype and clinical trials – 37 successful humans cases.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy based on telomerase. Telomerase is the enzyme that controls the potential of cellular proliferation, and which is reactivated in 90% of human cancers (Nobel Prize 2009). So far, a major limitation in the development of an effective telomerase immunotherapy has been the technical impossibility to produce significant amount of telomerase protein, but recently a breakthrough system now allows its large-scale production (PMID: 25958399). Telomium implements this new technology which furthermore supports the preparation of a cancer vaccine of a completely new class in the pharmacopoeia: a ribonucleoprotein vaccine, which has the special ability to reproduce the mechanisms operating in autoimmunity that breaks immune tolerance. This self-adjuvanted and self-vectored telomerase ribonucleoprotein vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology. By inducing a full activation of the immune system against cells producing telomerase (=the cancer cells in an adult body), our product has the ability to induce an autoimmune reaction targeted against any form of cancer, without causing significant side effects. Given the almost universal presence of telomerase in human cancers our product has the potential to extend the efficiency of immune checkpoint-inhibitors from the current minority to a majority of patients.
TOLREMO is an ETH Spin-off founded in March 2017. The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. The company’s innovative therapeutic approach specifically eradicates those cancer cells that ultimately cause drug resistance. Its science-based drug discovery and development pipeline is fueled by a unique screening platform for which a patent has been filed. TOLREMO’s vision is to use its personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and expert in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientist who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.
Virility Medical is a clinical stage venture, engaged in the development and commercialization of treatment for premature ejaculation by method of neuromodulation. Virility’s product is an intimate perineal skin patch. The patch carries an electronic module that delivers transcutaneous neuromuscular electrical stimulation to the adjacent nerves and muscles. Thus, the muscles are electrically inhibited and, the premature initiation of the ejaculation phase is delayed for the duration of stimulation, after which the patch is disposed of.
Responsive Web Design powered by 